Ablok Plus

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ablok Plus

Property Description
Active Ingredients Atenolol, Chlorthalidone
Form Oral Tablet (Fixed-dose combination)
Pharmacological Class Antihypertensive Agent
Common Use Management of persistent High Blood Pressure (Hypertension)
Origin Synthetic/Derived

Defining Ablok Plus: Identity and Classification

Ablok Plus is a prescription-only pharmaceutical product that serves as an antihypertensive agent used for the management of high blood pressure. This medicine is defined as a fixed-dose combination product, combining the active ingredients Atenolol and Chlorthalidone in a single oral tablet. This dual-agent therapy approach is clinically recognized for its ability to provide comprehensive, sustained control over elevated blood pressure, often proving more effective than monotherapy in certain patient groups.

Composition and Form: Atenolol, Chlorthalidone, and Dual-Agent Therapy

The two synthetic/derived components are the beta1-selective beta-blocker Atenolol and the thiazide-like diuretic Chlorthalidone. The combination is sometimes generically referred to as Co-tenidone. This specific pairing is distinguished by combining a cardioselective agent (Atenolol), which reduces heart workload, with a diuretic that possesses a notably sustained duration of action (Chlorthalidone), facilitating effective fluid management over a full day. The formulation is available globally under several brands, demonstrating its status as a widely accepted treatment strategy.

General Purpose: What Is This Medicine Used For?

The ultimate purpose of Ablok Plus is the reliable and consistent management of persistent high blood pressure (hypertension). This integrated approach, which targets both the heart's pumping force and the body's fluid volume, is a core method for mitigating cardiovascular risk. The general benefit is to help adult patients maintain blood pressure within a target range, thereby reducing the chronic strain that uncontrolled hypertension places on the vascular system, heart, and kidneys.

Regulatory References

  1. DailyMed - NIH
  2. StatPearls - NIH

What side effects are possible with Ablok Plus?

Possible Side Effects and Safety Information

The official safety profile for the fixed-dose combination of Atenolol and Chlorthalidone (Ablok Plus) is documented by governmental regulatory authorities (such as the FDA and EMA), classifying potential adverse reactions by system and frequency.

Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized to describe their likelihood of occurrence:

  • Common (affecting 1 to 10 users in 100): Includes systemic effects such as fatigue, dizziness, bradycardia (slow heart rate), cold extremities, and gastrointestinal disturbances. Metabolic effects like hypokalemia (low potassium) and hyperuricaemia (high uric acid) are also common.
  • Rare (affecting 1 to 10 users in 10,000): Involve effects on the Nervous System and Psychiatric Disorders such as confusion, hallucinations, and mood changes. Rare cardiovascular effects include the potential worsening of heart failure and the precipitation of heart block.

System-Organ Classes and Serious Safety Considerations

The product's labeling classifies reported effects across several body systems, including Cardiac Disorders, Vascular Disorders, Metabolism and Nutrition Disorders, and Skin and Subcutaneous Tissue Disorders.

Serious adverse reactions documented in official sources include the risk of bronchospasm, especially in susceptible patients, and the potential for severe electrolyte imbalances due to the diuretic component. Regulatory documentation also advises that the sudden cessation of the beta-blocker component can lead to Abrupt Cessation Syndrome, with possible exacerbation of angina.

Population-Specific Constraints

The official safety profile includes specific constraints: the medication is Contraindicated in individuals with pre-existing conditions such as Severe Bradycardia, Cardiogenic Shock, and Decompensated Heart Failure. Caution is required in older adults and patients with renal or hepatic impairment, as reduced organ function may necessitate close monitoring. The safety and efficacy of the combination have not been established in the pediatric population.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose manifestations for Ablok Plus are officially documented as an exaggeration of the effects of its two components, Atenolol and Chlorthalidone. Due to the Atenolol component, overdose may present with bradycardia (slow heart rate), severe hypotension, acute cardiac failure, and difficulty breathing due to bronchospasm. Additionally, hypoglycemia (low blood sugar) is a noted manifestation. The Chlorthalidone component contributes to severe electrolyte imbalance, such as hypokalemia, which can manifest as profound weakness, lethargy, or nausea.

Official regulatory documents classify the potential outcomes of overdose as severe, including life-threatening events such as cardiac arrest, cardiogenic shock, and severe, unmanaged electrolyte disturbances. Because of these serious risks, immediate medical attention is required for any suspected overdose. It is officially mandated to contact emergency services if the affected individual has collapsed, seized, or cannot be awakened.

Management is strictly symptomatic and supportive. The regulatory information notes that no specific antidote is known for the Atenolol component. Treatment may include procedures to remove the unabsorbed drug, such as gastric lavage or administration of activated charcoal. Cumulative effects in the presence of overdose are noted as a specific consideration for patients with impaired renal function.

Therapeutic Uses of Ablok Plus

Ablok Plus is commonly used across therapeutic domains where additional symptomatic support is needed, primarily for managing cardiovascular conditions. As a core component, the medication is applied in addressing conditions, including hypertension (high blood pressure) and symptoms related to angina (chest pain).

This combination therapy may be part of symptomatic management applied in clinical settings that involve acute or unstable symptom patterns, such as periods of heightened symptoms associated with elevated blood pressure. The drug supports patients dealing with conditions marked by increased physiological stress, and its use is relevant for easing the overall symptom burden. The medication helps improve day-to-day comfort during symptomatic periods where symptoms interfere with routine activities. The combination may contribute to improved comfort during periods of heightened symptoms.

The combination is used in situations involving recurrent or episodic manifestations, providing supportive relief when symptoms interfere with routine activities. It assists with symptomatic management and supports general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus overview of Atenolol

Eligibility and Restrictions for Use

Who Can and Cannot Use Ablok Plus?

Eligibility for Ablok Plus, a combination of Atenolol (a beta-blocker) and Chlorthalidone (a diuretic), is defined by strict regulatory guidelines regarding existing health conditions and patient demographics.

Absolute Contraindications

Ablok Plus must not be used if a patient has:

  • Severe cardiovascular conditions, including uncontrolled heart failure, cardiogenic shock, severe bradycardia (abnormally slow heart rate), or certain types of second- or third-degree heart block.
  • Anuria (absence of urine formation), metabolic acidosis, or untreated phaeochromocytoma (a tumor of the adrenal gland).
  • Known hypersensitivity to Atenolol, Chlorthalidone, or sulfonamide-derived medicines.

Restricted Use and Special Populations

Use of this medicine is restricted or requires caution in several populations due to potential risks or lack of data:

  • Renal or Hepatic Impairment: Requires dose adjustment and close monitoring, especially in cases of severe kidney impairment.
  • Pregnancy and Lactation: Use is generally not recommended or highly restricted due to documented risks to the fetus or neonate.
  • Children and Adolescents: Ablok Plus is not recommended for the paediatric population because its safety and efficacy have not been established by official regulatory data.
  • Bronchial Asthma: Patients with obstructive airway disease require extreme caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes officially documented interactions for Ablok Plus (atenolol/chlorthalidone) based on government regulatory information.


Documented Interaction Classifications

Classification Examples of Interacting Substances/Classes
Contraindicated Combinations Disopyramide, Verapamil (IV), Diltiazem (IV).
Clinically Significant Interactions NSAIDs (e.g., Indomethacin), Digitalis Glycosides, Lithium, Catecholamine Depleting Drugs (e.g., Reserpine).

Pharmacodynamic and Exposure-Based Interactions

Interactions are defined by their effect on drug action or concentration. Additive pharmacodynamic effects are documented with other blood pressure or heart rate-lowering agents, increasing the risk of severe bradycardia and hypotension. The chlorthalidone component is documented to reduce the renal clearance of Lithium, which can lead to increased serum concentrations and toxicity requiring careful monitoring.

Timing and Absorption Constraints

Specific interactions are based on interference with the absorption of atenolol. The co-administration of Aluminium Hydroxide antacids and certain multivitamin/mineral supplements is documented to decrease atenolol exposure. To manage this, regulatory information requires that these products be separated in time (e.g., administered at least 2 hours apart) from Ablok Plus.

Population Considerations

Official labeling notes that the beta-blocker component can mask the signs of hypoglycemia in diabetic patients. Interaction risks are also heightened for patients with severe renal impairment due to the potential for drug accumulation.

Mechanism of Action

How Ablok Plus Works: Mechanism of Action

Ablok Plus acts via the co-action of two distinct mechanistic domains: modulation of the sympathetic nervous system and regulation of renal fluid volume.

1. Modulation of Cardiac Drive and Hormonal Signaling

Atenolol functions as a beta1-selective antagonist, binding to and suppressing beta1-adrenergic receptors on cardiac tissue and the renal juxtaglomerular apparatus. This action blocks catecholamine signaling, initiating a cascade that results in a lower heart rate, reduced force of contraction, and decreased renin release. The physiological effect is a reduction in cardiac output and the dampening of hormonal signals that induce vasoconstriction.

2. Targeted Regulation of Fluid and Electrolyte Balance

Chlorthalidone, a thiazide-like diuretic, acts as a specific inhibitor on the Na^+/ Cl^- cotransporter (NCC) in the kidney's distal convoluted tubule. This mechanism blocks the reabsorption of sodium and chloride, leading to increased excretion of salt and water (natriuresis and diuresis). The resulting physiological effect is a decrease in circulating plasma volume and, over time, a reduction in the overall peripheral vascular resistance.

3. Interaction Between Mechanistic Domains

The combined mechanism operates by targeting both the pressure component (sympathetic drive/vasoconstriction) and the volume component (fluid retention) of cardiovascular regulation. The combined physiological consequence is an integrated reduction in mean arterial pressure. The mechanisms interact to influence separate regulatory pathways, which together modulate cardiovascular and volume dynamics.

Dosage and Administration Information

How Ablok Plus Is Used: Official Administration Guidelines

Ablok Plus, a fixed-dose combination tablet containing atenolol and chlorthalidone, must be used according to the official prescribing information. It is intended for the long-term, chronic management of high blood pressure (hypertension) and is not indicated for the initial treatment of this condition.


Standard Administration and Dosing

Category Official Instruction
Route of Administration Oral (by mouth).
Dosing Schedule Once daily. Typical maintenance doses are one tablet of 50 mg Atenolol / 25 mg Chlorthalidone or 100 mg Atenolol / 25 mg Chlorthalidone.
Timing The tablet may be taken with or without food.
Preparation Tablets must be swallowed whole with water.

Procedural and Population-Specific Rules

The full blood pressure-lowering effect for a given dose may take one to two weeks to establish. Dosage adjustments, if needed, should be made at weekly or longer intervals.

Administration Restrictions

  • Discontinuation: Therapy must not be stopped abruptly. The medication should be withdrawn gradually over a period, such as 7 to 14 days, to avoid potential complications, particularly in patients with ischemic heart disease.
  • Pediatric Use: The use of this combination is not recommended in children due to a lack of established safety and efficacy data.
  • Renal Impairment: Dose modifications are necessary for the Atenolol component in patients with impaired kidney function (e.g., Creatinine Clearance < 35 mL/min). The combination is generally not administered in cases of severe impairment.

These instructions define a structured approach to use, establishing Ablok Plus as a once-daily, supervised, chronic treatment that requires specific handling when starting or stopping therapy.

Recent Clinical Evidence

Evidence for Use in Managing Essential Hypertension

Research included Randomized Controlled Trials (RCTs) where the fixed-dose combination was evaluated in adult populations with essential hypertension. These studies research examined how blood pressure levels—both systolic and diastolic—changed during the study period and monitored the achievement of specific target blood pressure goals. Findings described patterns observed in the studies related to the measurement of these levels.


Research Comparing Combination Therapy Approaches

A specific area of research studies explored the difference between taking the fixed-dose pill (FDC) versus the same ingredients as separate tablets (FEC). Some systematic reviews reported that final BP measurements did not show a significant difference between the FDC and FEC groups. However, findings were mixed across studies, and some trials described patterns related to the patient’s reported treatment regimen.


Patient Adherence Studies and Persistence

Research applied in observational settings has focused on how the FDC approach affects medication adherence and persistence. Studies data show patterns related to adherence and persistence, suggesting that the FDC format was observed in some studies to affect consistency in taking the medicine over time compared to the separate pills.


Long-Term Studies and Follow-Up

Research was studied for its impact over defined time intervals. While efficacy trials focused on short-term changes, other observational cohorts were observed in extended settings lasting several years. These longer research studies monitored the incidence of composite endpoints (e.g., major cardiovascular events). However, the long-term effects are not fully established, and some efficacy trials have follow-up durations that were limited.


Evidence in Special Populations

Research examined specific demographic groups, and studies research describes the experience of older adults with essential hypertension. However, data for certain groups remain insufficient. For example, limited data are available on the relationship of age to the effects of the combination in the pediatric population. Research does not determine whether an individual will respond similarly across all groups.


What Research Shows and Where Uncertainty Remains

The body of research contributes to the broader evidence landscape for the management of high blood pressure. One limitation is that the fixed dosage does not allow for the flexible adjustment of the individual component doses, which was observed in some studies to limit the options for individual dose changes. Furthermore, the results apply only to the populations studied, meaning the evidence contributes to understanding symptom patterns but certainty remains low for individual outcomes.

Frequently Asked Questions (FAQ)

Common questions about Ablok Plus (FAQ)

Q: Is Ablok Plus the same as other 'beta-blockers'?

A: Ablok Plus is a fixed-dose combination product containing a beta1-selective beta-blocker (atenolol) and a diuretic (chlorthalidone). While one component is a beta-blocker, the medicine works by combining two different actions—modulating heart function and regulating fluid balance—which distinguishes it from single-ingredient beta-blocker medicines.

Q: Does Ablok Plus cause weight gain?

A: Regulatory documents describe a risk of unusual weight gain as a potential sign of an underlying medical issue, which should be reported. Weight gain is not generally listed as a common, isolated side effect, but documented concerns exist regarding fluid retention and edema associated with the diuretic component.

Q: Is it normal to have vivid dreams while taking Ablok Plus?

A: Adverse reaction reports associated with the beta-blocker component (atenolol) include central nervous system effects such as vivid dreams or sleep disturbances. Regulatory documents classify these effects among the less common psychiatric and nervous system-related events.

Q: Can Ablok Plus be taken at any time of day?

A: The drug is officially prescribed to be taken once daily. The official label specifies it can be taken with or without food. The specific timing can be based on factors discussed with a healthcare provider.

Q: What happens if you suddenly stop taking Ablok Plus?

A: Regulatory guidelines strongly state that therapy must not be stopped abruptly. Suddenly stopping the beta-blocker component can lead to an Abrupt Cessation Syndrome, with reported risks of exacerbated angina (chest pain) and, in certain patients, myocardial infarction (heart attack).

Q: What research supports the use of Ablok Plus for high blood pressure?

A: The medicine is officially indicated for the treatment of high blood pressure (hypertension), an approval supported by evidence from controlled trials. These studies examined how lowering blood pressure affects the risk of cardiovascular events, such as stroke and myocardial infarction.

Q: Does the use of Ablok Plus require regular blood tests?

A: Official documents advise on the need for periodic determinations of serum electrolytes (such as potassium levels). This monitoring is necessary because the diuretic component (chlorthalidone) can potentially cause electrolyte imbalances, which are subject to monitoring according to official guidelines.

Q: Can Ablok Plus cause sexual side effects?

A: Adverse reaction reporting includes changes in sex drive or performance as a possible, though typically uncommon, side effect associated with the medication. These effects are included among the documented reports in official safety profiles.

Q: Is Ablok Plus only for high blood pressure or other heart conditions too?

A: The fixed-dose combination Ablok Plus is specifically approved and indicated for the treatment of hypertension (high blood pressure). Its official use is not extended to other heart conditions as a combination therapy.

Q: Can Ablok Plus affect mood?

A: Official safety documents list mood changes or feelings of depression as a documented, though rare, adverse effect. These effects are part of the reported potential impacts on the central nervous system and psychiatric disorders.

Q: What should be monitored by a doctor while taking Ablok Plus?

A: Regulatory guidance advises monitoring several factors, including blood pressure, heart rate, serum electrolytes, and potential signs of hypoglycemia (low blood sugar) in patients with diabetes. This guidance is based on official warnings and precautions.

Q: Can Ablok Plus be taken with pain relievers like ibuprofen?

A: Official interaction documents classify Non-Steroidal Anti-Inflammatory Drugs (NSAIDs, which includes ibuprofen) as substances that can reduce the blood pressure-lowering effects of the active components.

Q: Does Ablok Plus affect blood sugar levels?

A: Regulatory labeling states that the beta-blocker component (atenolol) may affect blood glucose levels. It can also mask the warning signs of low blood sugar (hypoglycemia) in patients with diabetes, which is a factor to consider during blood sugar monitoring.

Q: Can older adults take Ablok Plus?

A: Official documents describe that older adults can use the drug. However, this population may be at a greater risk for certain adverse effects and may require dosage reduction or close monitoring, consistent with general geriatric use guidelines.

Q: Can I take cold and flu medicine while using Ablok Plus?

A: Many over-the-counter cold and flu medicines contain sympathomimetic agents. Official labeling states that these agents can increase blood pressure and may potentially counteract the blood pressure-lowering effects of Ablok Plus.

Q: What are the serious, but rare, side effects of Ablok Plus?

A: The official safety profile documents several rare but serious concerns. These include the risk of bronchospasm (narrowing of airways), severe electrolyte imbalances (salt/water disruption), and the potential for worsening of heart failure in susceptible patients.

Q: Does Ablok Plus cause dizziness or lightheadedness?

A: Official adverse reaction reporting classifies dizziness as a common side effect. Lightheadedness is also documented and may occur as a symptom of low blood pressure (hypotension) or slow heart rate (bradycardia), which are also listed effects.

Q: How is Ablok Plus different from just taking Atenolol?

A: Ablok Plus is a fixed-dose combination that includes the beta1-selective beta-blocker atenolol plus the diuretic chlorthalidone. It differs from atenolol monotherapy because it employs a dual mechanism that addresses both heart function and fluid volume regulation to achieve blood pressure lowering.

Q: Can Ablok Plus affect sleep patterns?

A: Adverse reaction reporting includes sleep disturbances or insomnia as documented effects associated with the beta-blocker component. These effects are classified among the less common central nervous system effects documented in official product information.

Q: What happens if Ablok Plus is taken with certain heart medications?

A: Official documents list contraindications with certain heart rate-lowering medicines, such as Disopyramide, Verapamil (IV), and Diltiazem (IV). Combining these can cause additive pharmacodynamic effects, increasing the risk of severely slow heart rate (bradycardia) and low blood pressure (hypotension).

Q: Are there different strengths of Ablok Plus available?

A: The fixed-dose combination is documented in official prescribing information to be available in at least two strengths. These typically combine atenolol and chlorthalidone in formulations such as 50 mg / 25 mg and 100 mg / 25 mg.

Q: What is the difference between Ablok Plus and another combination blood pressure pill?

A: Ablok Plus is classified as a specific combination of a beta-blocker (beta1-selective atenolol) and a thiazide-like diuretic (chlorthalidone). Other combination pills may use different drug classes, such as ACE inhibitors or Calcium Channel Blockers combined with a diuretic, reflecting a difference in their mechanism of action.

Q: Does Ablok Plus interact with cold remedies containing pseudoephedrine?

A: Official interaction documents state that products containing pseudoephedrine (a sympathomimetic agent found in some cold remedies) can increase blood pressure. Official documents note that these agents can counteract the antihypertensive effects of Ablok Plus.

Q: Is the tiredness from Ablok Plus temporary?

A: Fatigue is listed in official sources as a common side effect. While the duration of this effect is not officially defined as temporary for all users, some regulatory documents note that such effects can lessen as the body adjusts to the medication over time.

Q: Is Ablok Plus known to cause dry mouth?

A: Dry mouth is documented in official product information as a reported adverse effect. This effect is often associated with the fluid-reducing action of the diuretic component (chlorthalidone).

How should Ablok Plus be stored and disposed of?

How to Store and Dispose of Ablok Plus

Ablok Plus (atenolol and chlorthalidone) must be stored strictly according to official regulatory documentation to maintain its stability and effectiveness.


Storage Requirements

  • Temperature: Store at Controlled Room Temperature, ideally between 20 C to 25 C (68 F to 77 F). Do not freeze.
  • Protection: The medicine must be protected from light and stored away from excess moisture.
  • Container: Tablets should be kept in a well-closed, light-resistant container.
  • Safety: Always store the medication out of the reach of children.

Disposal Instructions

Disposal: Unused or expired Ablok Plus must not be discarded in household trash or poured down a sink or toilet. Official guidance requires consulting a healthcare professional or using an authorized medication take-back program for safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ablok Plus found in:

A-Z Index: